Sugi Predict

Sugi Predict / Compounds / SCHEMBL3397668

SCHEMBL3397668

SCHEMBL3397668

CC(C)(C)OC(=O)NCCI

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.58
▸ MEN1 O00255 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ MAOA P21397 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ CA12 O43570 6/20 0.47
▸ CA1 P00915 6/20 0.47
▸ CA2 P00918 5/20 0.47
▸ CA9 Q16790 5/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NQO2 P16083 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ MALT1 Q9UDY8 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2501870 0.88 TDP1 (0.65) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3341020 0.86 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2233648 0.86 TDP1 (0.68) TDP1MEN1GAAKMT2AMAOA
SCHEMBL606524 0.84 TDP1 (0.60) TDP1MEN1GAAKMT2AMAOA
SCHEMBL30167422 0.84 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL1616400 0.84 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7527044 0.84 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2702906 0.84 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL29368579 0.84 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2539526 0.83 TDP1 (0.50) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743457-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2026-05-20 — — EP disclosed
US-20260132149-A1 Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith BEONE MEDICINES I GMBH (CH) 2026-05-14 — — US disclosed
US-12509470-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-12-30 — — US disclosed
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
WO-2025015045-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2025-01-16 — — WO disclosed
CN-117843578-A Selenium ester compound, preparation method and medical application thereof 舒蒙(苏州)生物医药有限公司 2024-04-09 — — CN disclosed
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 — — US disclosed
EP-3298003-B1 BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2023-04-19 — — EP disclosed
US-11572367-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2023-02-07 — — US disclosed
US-11505558-B1 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2022-11-22 — — US disclosed
WO-2005032484-A9 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO (US) 2006-05-18 — — WO disclosed
WO-2005032484-A2 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-14 — — WO disclosed
US-20030199544-A1 Farnesyltransferase inhibitors ABBOTT LABORATORIES 2003-10-23 — — US disclosed
US-20030199542-A1 Farnesyltransferase inhibitors WEINSTOCK, STEVEN F. 2003-10-23 — — US disclosed
US-6630488-B1 Quinolizinones as integrin inhibitors BIOCHEM PHARMA, INC. (CA) 2003-10-07 — — US disclosed
EP-1115724-A1 QUINOLIZINONES AS INTEGRIN INHIBITORS Shire Biochem Inc. (CA) 2001-07-18 — — EP disclosed
WO-2000017197-A1 QUINOLIZINONES AS INTEGRIN INHIBITORS BIOCHEM PHARMA INC. (US) 2000-03-30 — — WO disclosed
US-5371220-A Bicyclo-heterocyclic intermediates for cephalosporin compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-12-06 — — US disclosed
US-5232918-A Bactericides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-03 — — US disclosed
US-5019570-A Antibioics IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509470-B2 Antiviral heterocyclic compounds NR3C1, ZC3HAV1, HAVCR2 TDP1 3036/4885MEN1 2420/4885GAA 4121/4885
US-20030199542-A1 Farnesyltransferase inhibitors FNTA, FNTB, LCAT TDP1 2251/4885MEN1 1091/4885GAA 329/4885
US-20030199544-A1 Farnesyltransferase inhibitors FNTA, FNTB, LCAT TDP1 2251/4885MEN1 1091/4885GAA 329/4885
US-11505558-B1 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 TDP1 2460/4885MEN1 1038/4885GAA 1445/4885
US-20260132149-A1 Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith MECP2, PRMT5, DNMT1 TDP1 437/4885MEN1 1017/4885GAA 4878/4885
US-11572367-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 TDP1 2460/4885MEN1 1038/4885GAA 1445/4885
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 TDP1 2460/4885MEN1 1038/4885GAA 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.